Eli Lilly’s Triple Agonist Retatrutide Achieves 21-23% Weight Loss in Diabetic and CVD Patients Over 80 Weeks, Nears FDA Submission

August 2, 2026

BioPharma Dive USA

Overview

Eli Lilly is preparing to seek FDA approval for its obesity drug retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors. New data from the Triumph-2 and Triumph-3 studies showed average body weight loss of 21% after 80 weeks in diabetic patients and 23% in cardiovascular disease patients at the highest doses. While demonstrating significant efficacy for weight loss, the drug’s side effect profile (nausea, diarrhea, constipation, vomiting) and its long-term impact on heart health are under close monitoring for optimal clinical integration.

In Depth

Key Findings

Eli Lilly is preparing to seek U.S. Food and Drug Administration (FDA) approval for its obesity drug, retatrutide. This novel triple agonist, which targets GLP-1, GIP, and glucagon receptors, has demonstrated impressive efficacy in new data from the Triumph-2 and Triumph-3 studies. These trials revealed an average body weight loss of 21% after 80 weeks in diabetic patients and 23% in cardiovascular disease (CVD) patients, both at the highest doses, signaling a potent new option in obesity management.

Technical / Clinical Details

Retatrutide employs a unique mechanism of action by simultaneously activating three incretin-like hormone receptors: GLP-1, GIP, and glucagon. This multi-targeted approach is believed to contribute to its superior weight loss effects by influencing multiple metabolic pathways, including appetite suppression, enhanced satiety, improved insulin secretion, and modulated glucagon release. The Triumph-2 study, focusing on patients with type 2 diabetes and obesity, reported an average weight loss of 21% over 80 weeks. The Triumph-3 study, involving CVD patients, showed a comparable 23% weight reduction over the same period. These results represent a significant improvement over existing single GLP-1 agonists or dual GLP-1/GIP agonists.

Regarding safety, gastrointestinal side effects such as nausea, diarrhea, constipation, and vomiting were reported, which are common with GLP-1 receptor agonists. Managing these side effects and monitoring the drug’s long-term cardiovascular impact will be crucial for its post-approval clinical application.

Background & Context

Obesity remains a global health crisis, escalating the risk of comorbidities like type 2 diabetes and cardiovascular disease. The new generation of obesity drugs, particularly GLP-1 receptor agonists, has shown remarkable efficacy compared to traditional treatments, carving out a substantial market. Eli Lilly aims to solidify its leadership in this domain with retatrutide, following the success of tirzepatide (a GLP-1/GIP dual agonist). Retatrutide’s triple agonist mechanism offers a distinct differentiation point, potentially providing a new, more powerful option for patients seeking aggressive weight reduction.

Strategic Significance & Outlook

The FDA submission for retatrutide has the potential to significantly alter the obesity treatment landscape. If approved, retatrutide could become a powerful new therapeutic choice for patients who have not achieved sufficient results with existing GLP-1 agonists or dual agonists, or for those desiring more pronounced weight loss. Future investigations will focus on long-term safety data, particularly concerning cardiovascular events and other metabolic markers. The drug’s high efficacy is also expected to intensify competition within the obesity treatment market, driving further innovation.

Source: https://www.biopharmadive.com/news/lilly-retatrutide-fda-application-obesity-drug-results/825987/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.